Japan's MHLW/PMDA recommends package insert revisions

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1732卷 / 1期

关键词：

D O I：

10.1007/s40278-018-55457-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：1 / 1

相关论文

共 50 条

[31] Japan's PMDA revises precautions for multiple products
Reactions Weekly, 2017, 1661 (1) : 4 - 4
[32] Japan's PMDA revises precautions for various products
Reactions Weekly, 2015, 1572 (1) : 6 - 6
[33] Japan's PMDA investigation results: June 2018
Reactions Weekly, 2018, 1706 (1) : 4 - 4
[34] Detection of Vaccine Adverse Events Before Package Insert Revisions Using a Japanese Spontaneous Reporting System
Suzuki, Shimon
Imai, Shungo
Mitsuboshi, Satoru
Kizaki, Hayato
Hashiguchi, Masayuki
Hori, Satoko
JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (08): : 903 - 908
[35] The PMDA's view on the limited pipeline of nephrology drugs in Japan
Tanaka, Mototsugu
Ikuma, Mutsuhiro
KIDNEY INTERNATIONAL, 2021, 100 (01) : 241 - 242
[36] Japan's PMDA releases updated risk report for telaprevir
Reactions Weekly, 2012, 1408 (1) : 2 - 2
[37] Japan's PMDA releases investigation results for 4 products
Reactions Weekly, 2015, 1541 (1) : 5 - 5
[38] Japan's PMDA releases investigation results for 4 products
Reactions Weekly, 2016, 1590 (1) : 3 - 3
[39] Japan's PMDA releases investigation results for 8 products
Reactions Weekly, 2016, 1595 (1) : 5 - 5
[40] Comment: Detection of Vaccine Adverse Events Before Package Insert Revisions Using a Japanese Spontaneous Reporting System
Noguchi, Yoshihiro
Yoshimura, Tomoaki
JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (10): : 1169 - 1170

← 1 2 3 4 5 →